3 REITs to Buy for Passive Income in July

July 2026 income investors get a more supportive rate backdrop: the 10-year Treasury is ~4% (down from a May peak near 5%), and the Fed Funds upper bound has held at 4% after two cuts in late 2025. The article highlights three REIT dividend/return stories: Realty Income keeps a ~5% yield with its June 2026 monthly raise to $0.27 and raised 2026 AFFO guidance to $4.41–$4.44; STAG Industrial’s quarterly payout is 38c (about a ~4% yield) alongside stronger Q4/2025 operating momentum but rising refinancing costs; Healthpeak’s monthly payout is 10c (near ~6% yield) after the Janus Living IPO delivered ~$880M net proceeds and included a major GAAP EPS beat ($0.28 vs $0.05). Net/net, falling rates should tighten bond-vs-dividend spreads, but key risks are valuation/full rates sensitivity at O, refinancing math at STAG, and lab demand/NOI softness at DOC.

Analysis

The setup is less about “income is back” and more about duration math. At a 4% 10-year, high-quality REITs trade like quasi-bonds with equity upside, but the gap between dividend yield and risk-free is now narrow enough that valuation discipline matters more than the headline payout. That makes the market likely to reward balance-sheet optionality and penalize any name with visible debt rollover or payout-format friction.

Among the group, O looks like the cleanest cash-flow compounder but also the least mispriced; it is already acting like a safety asset, so the next leg higher likely requires another downshift in rates or an AFFO reacceleration that offsets premium multiple risk. STAG is the more fragile setup: the shift away from monthly distributions may look cosmetic, but it can matter for retail-holder persistence and could amplify drawdowns if refinancing costs stay sticky. DOC has the best asymmetry because the market is still digesting the value of the retained stake in JAN; if lab leasing stabilizes, investors may start valuing the operating REIT on cash flow while treating the stake as a separate liquid asset, which can support rerating.

Contrarian view: consensus is probably overpaying for “monthly income” branding and underpricing cadence risk. The real medium-term driver is whether these REITs can keep growing AFFO faster than debt costs; if the 10-year backs up toward 4.5%+ or credit spreads widen, the highest-multiple names will compress first. Falsifiers: O missing AFFO guidance or a jump in tenant impairments, STAG seeing further debt-cost step-ups without offsetting rent spreads, or DOC’s lab NOI failing to inflect by late summer.

Key Decisions for Investors

• Prefer a pair trade: long DOC / short O into the next 1-3 months. DOC has more embedded rerating potential from the JAN stake and buybacks, while O already discounts much of the rate tailwind; exit if O can sustain a move above its current yield-equivalent support or if DOC lab NOI deteriorates again.
• Avoid chasing STAG as a pure income substitute. If maintaining exposure, keep it as a small tactical long only on pullbacks; the monthly-to-quarterly payout change likely weakens retail demand and can leave the stock vulnerable if refinancing spreads widen over the next 2 quarters.
• Use O as a defensive hold, not a momentum long. Best entry is on any selloff tied to a 10-year move back above 4.25%-4.5%; below that, upside is likely capped unless 2026 AFFO guidance is raised again.
• Watch JAN as an event-driven stub, not an income trade. If the market starts valuing the retained stake at a meaningful discount to the implied IPO mark, there may be a short-term arb/rerating opportunity; if liquidity is thin, treat it as a watchlist name rather than a core position.
• Set a macro trigger on the 10-year at 4.5%. Above that level, reduce REIT beta broadly and favor names with lower leverage and higher internal growth over high-multiple yield plays.